Peptide inhibiting platelet derived growth factor (PDGF-BB) and fibroblast growth factor (bFGF) activity

Abstract

A novel peptide, derived from the human fibroblast growth factor (bFGF), is identified. Said molecule is able to inhibit in vitro the effects of Platelet Derived Growth Factor (PDGF-BB) and basic Fibroblast Growth Factor (bFGF) on primary rat smooth muscle cells (RASMC) and primary bovine endothelial cells (BAEC). Said molecule is also able to inhibit in vivo angiogenesis CD1 mice.

1 . A method for inhibiting platelet derived growth factor (PDGF-BB) and fibroblast growth factor (bFGF) in a subject comprising administering to said subject an effective amount of a peptide, said peptide having the following primary structure: 
 Asp-Pro-His-Ile-Lys-Leu-Gln-Leu-Gln-Ala-Glu (Seq Id No: 1)    
     
     
         2 . A method to affect cell proliferation in a subject comprising administering to said subject an effective amount of a peptide, said peptide having the following primary structure: 
 Asp-Pro-His-ILe-Lys-Leu-Gln-Leu-Gln-Ala-Glu (SEQ ID NO: 1).    
     
     
         3 . The method according to  claim 2 , where said method inhibits cell migration and tumor cell migration toward potential metastasis sites comprising administering an effective amount of said peptide.  
     
     
         4 . The method according to  claim 2 , wherein said method inhibits a primary tumor growth and metastasis comprising administering an effective amount of said peptide.  
     
     
         5 . A method for the preparation of a pharmacological compound comprising adding a peptide of SEQ ID NO: 1 to an excipient.  
     
     
         6 . A method for the treatment of vascular diseases in a subject comprising administering to said subject an effective amount of a peptide, said peptide having the following primary structure: 
 Asp-Pro-His-ILe-Lys-Leu-Gln-Leu-Gln-Ala-Glu (SEQ ID NO: 1).    
     
     
         7 . The method according to  claim 6 , wherein thrombotic events and related pathologies in a subject are treated by administering to said subject an effective amount of said peptide.